Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study
| dc.contributor.author | Monera-Penduka, Tsitsi G | |
| dc.contributor.author | Maponga, Charles C | |
| dc.contributor.author | Wolfe, Alan R | |
| dc.contributor.author | Wiesner, Lubbe | |
| dc.contributor.author | Morse, Gene D | |
| dc.contributor.author | Nhachi, Charles F B | |
| dc.date.accessioned | 2017-04-04T08:41:05Z | |
| dc.date.available | 2017-04-04T08:41:05Z | |
| dc.date.issued | 2017-03-14 | |
| dc.date.updated | 2017-03-14T19:02:21Z | |
| dc.description.abstract | Background: Moringa oleifera Lam., an herb commonly consumed by HIV-infected people on antiretroviral therapy, inhibits cytochrome P450 3A4, 1A2 and 2D6 activity in vitro; and may alter the pharmacokinetics (PK) of antiretroviral drugs metabolized via the same pathways. However, in vitro drug interaction activity may not translate to a clinically significant effect. Therefore, the effect of moringa leaf powder on the PK of nevirapine in HIV-infected people was investigated. Methods: Adult patients at steady-state dosing with nevirapine were admitted for 12-h intensive PK sampling follow ing a 21-day herbal medicine washout. Blood sampling was repeated after 14 days of nevirapine and moringa (1.85 g leaf powder/day) co-administration. Nevirapine plasma concentrations were determined by liquid chromatographytandem mass spectrometry. To assess the effect of moringa on nevirapine PK, the change in nevirapine area under the plasma concentration–time curve (AUC) was determined. The mean difference in pre- and post-moringa nevirapine, maximum concentration (Cmax) and concentration at 12 h (C12h) were also calculated. The PK parameters were com pared by assessing the post/pre geometric mean ratios (GMRs) and associated 90% confidence intervals (CIs). Results: Pharmacokinetics analyses were performed on the results from 11 participants for whom complete data were obtained. The post/pre GMRs and associated 90% CIs for nevirapine were 1.07 (1.00–1.14) for the AUC; 1.06 (0.98–1.16) for Cmax and 1.03 (0.92–1.16) for C12h. Conclusion: Co-administration of Moringa oleifera Lam. leaf powder at the traditional dose did not significantly alter the steady-state PK of nevirapine. Trial registration number NCT01410058 (ClinicalTrials.gov) | |
| dc.identifier.apacitation | Monera-Penduka, T. G., Maponga, C. C., Wolfe, A. R., Wiesner, L., Morse, G. D., & Nhachi, C. F. B. (2017). Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. <i>AIDS Research and Therapy</i>, http://hdl.handle.net/11427/24144 | en_ZA |
| dc.identifier.chicagocitation | Monera-Penduka, Tsitsi G, Charles C Maponga, Alan R Wolfe, Lubbe Wiesner, Gene D Morse, and Charles F B Nhachi "Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study." <i>AIDS Research and Therapy</i> (2017) http://hdl.handle.net/11427/24144 | en_ZA |
| dc.identifier.citation | Monera-Penduka, T. G., Maponga, C. C., Wolfe, A. R., Wiesner, L., Morse, G. D., & Nhachi, C. F. (2017). Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. AIDS research and therapy, 14(1), 12. | |
| dc.identifier.ris | TY - Journal Article AU - Monera-Penduka, Tsitsi G AU - Maponga, Charles C AU - Wolfe, Alan R AU - Wiesner, Lubbe AU - Morse, Gene D AU - Nhachi, Charles F B AB - Background: Moringa oleifera Lam., an herb commonly consumed by HIV-infected people on antiretroviral therapy, inhibits cytochrome P450 3A4, 1A2 and 2D6 activity in vitro; and may alter the pharmacokinetics (PK) of antiretroviral drugs metabolized via the same pathways. However, in vitro drug interaction activity may not translate to a clinically significant effect. Therefore, the effect of moringa leaf powder on the PK of nevirapine in HIV-infected people was investigated. Methods: Adult patients at steady-state dosing with nevirapine were admitted for 12-h intensive PK sampling follow ing a 21-day herbal medicine washout. Blood sampling was repeated after 14 days of nevirapine and moringa (1.85 g leaf powder/day) co-administration. Nevirapine plasma concentrations were determined by liquid chromatographytandem mass spectrometry. To assess the effect of moringa on nevirapine PK, the change in nevirapine area under the plasma concentration–time curve (AUC) was determined. The mean difference in pre- and post-moringa nevirapine, maximum concentration (Cmax) and concentration at 12 h (C12h) were also calculated. The PK parameters were com pared by assessing the post/pre geometric mean ratios (GMRs) and associated 90% confidence intervals (CIs). Results: Pharmacokinetics analyses were performed on the results from 11 participants for whom complete data were obtained. The post/pre GMRs and associated 90% CIs for nevirapine were 1.07 (1.00–1.14) for the AUC; 1.06 (0.98–1.16) for Cmax and 1.03 (0.92–1.16) for C12h. Conclusion: Co-administration of Moringa oleifera Lam. leaf powder at the traditional dose did not significantly alter the steady-state PK of nevirapine. Trial registration number NCT01410058 (ClinicalTrials.gov) DA - 2017-03-14 DB - OpenUCT DO - 10.1186/s12981-017-0140-4 DP - University of Cape Town J1 - AIDS Research and Therapy LK - https://open.uct.ac.za PB - University of Cape Town PY - 2017 T1 - Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study TI - Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study UR - http://hdl.handle.net/11427/24144 ER - | en_ZA |
| dc.identifier.uri | http://dx.doi.org/10.1186/s12981-017-0140-4 | |
| dc.identifier.uri | http://hdl.handle.net/11427/24144 | |
| dc.identifier.vancouvercitation | Monera-Penduka TG, Maponga CC, Wolfe AR, Wiesner L, Morse GD, Nhachi CFB. Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. AIDS Research and Therapy. 2017; http://hdl.handle.net/11427/24144. | en_ZA |
| dc.language.iso | en | |
| dc.publisher | BioMed Central | |
| dc.publisher.department | Department of Medicine | en_ZA |
| dc.publisher.faculty | Faculty of Health Sciences | en_ZA |
| dc.publisher.institution | University of Cape Town | |
| dc.rights | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License | |
| dc.rights.holder | The Author(s) | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.source | AIDS Research and Therapy | |
| dc.source.uri | https://aidsrestherapy.biomedcentral.com/ | |
| dc.subject.other | Moringa oleifera | |
| dc.subject.other | Nevirapine | |
| dc.subject.other | Pharmacokinetics | |
| dc.subject.other | HIV | |
| dc.title | Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study | |
| dc.type | Journal Article | |
| uct.type.filetype | Text | |
| uct.type.filetype | Image | |
| uct.type.publication | Research | en_ZA |
| uct.type.resource | Article | en_ZA |